“AstraZeneca signs $735 million pact with Nektar” (PharmaTimes)
“Reports claim Nycomed has bid for Solvay drug division” (PharmaTimes)
“GSK to buy a $150 million stake in Dr Reddy’s?” (PharmaTimes)
“Biogen Idec Commences Tender Offer for Facet Biotech” (PharmaLive)
“Rexahn Pharmaceuticals and Teva Pharmaceutical Industries Close on a License Agreement” (PharmaLive)
“Ahead of the Bell: Genzyme downgraded to ‘Perform’” (Associated Press)
“Global Alzheimer’s cases expected to rise sharply” (USA Today)
“Possible successor to Kennedy is top pharma lobbyist” (littlesis.org)
“King Announces Commercial Availability of EMBEDA” (pharmalive.com)
“EURX: Hot Stocks” (flyonthewall.com)
At the UBS Global Life Sciences conference, Eurand (EURX) Chief Commercial Officer John Fraher said the company currently has 15 products in development, five in late-stage, including Zenpep.
This is copyright protected information, to receive the full article, please click here to sign up and register.
SUBSCRIBE